Using Chromatin Immunoprecipitation assays, they found that trabectedin treatment significantly reduced EWSR1::WT1 binding to the promoter of three genes highly expressed in DSRCT (Uboldi et al., 2017). This evidence concerns the gene EWSR1 and desmoplastic small round cell tumor.